Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women
Salim Abdool Karim; Angela D. M. Kashuba; Lise Werner; Quarraisha Abdool Karim
- Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women
Abdool Karim, Salim
Kashuba, Angela D. M.
Abdool Karim, Quarraisha
- Permanent URL:
- Book/Journal Title:
- The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposure prophylaxis (PrEP) in women, FEM-PrEP, is a substantial setback for HIV prevention. Expectations of this trial were high in view of favourable results from the pre-exposure prophylaxis initiative (iPrEX) trial, which studied the same drug and dosing strategy in men who have sex with men, and the Centre for the AIDS Programme of Research in South Africa (CAPRISA 004) trial,3 which tested tenofovir gel (a topical PrEP formulation) in heterosexual women. As a result, the interim FEM-PrEP trial results, announced on April 18, 2011, which showed no protection against HIV infection, were disappointing. Using publicly available information and data from other PrEP studies, we offer a potential explanation for the results of the FEM-PrEP trial.
- Publisher DOI:
- Item views: